Heading to Tumor Models San Francisco? Catch up with Steve Reed and Erin Trachet at our booth, or join Erin for her talk, Obesity & Immunotherapy: GLP-1R Agonist and Anti-PD-1 Response in the DIO MC38 Model, tomorrow at 2:15pm. See you there! #TumorModelsSF #TD2Oncology #OncologyCRO #PreclinicalResearch #CDX #PDX #ImmunoOncology
About us
TD2 Oncology is an oncology-focused Contract Research Organization (CRO) that supports improved and accelerated development of medicines for life-threatening diseases. We help companies move their drugs through the critical stages of preclinical, regulatory and clinical trial processes. Our scientific depth, proactive problem solving, and strategic direction and advice increase the likelihood of positive outcomes that bring hope and a better quality of life to cancer patients and their families. TD2 was born from the Translational Genomics Research Institute (TGen) as a nonprofit in 2003. TGen’s deep scientific expertise and approach to interrogating the “omic” drivers of disease is at the heart of TD2’s heritage and has become the foundation upon which TD2 creates unique clinical strategies for its clients.
- Website
-
http://www.td2inc.com
External link for TD2 Oncology
- Industry
- Research Services
- Company size
- 51-200 employees
- Headquarters
- Scottsdale, Arizona
- Type
- Privately Held
- Specialties
- Xenograft Models, Bioanalytical Services, Primary GBM Panel, Oncology clinical trial management, IND Filings, Regulatory Affairs, FDA Interactions, Data Management, Preclinical oncology, Translational drug development, Flow Cytometry, ADC Drug Development, Radiopharmaceutical Drug Development, Syngeneic Studies, Immuno-oncology, PDX Models, and Humanized PDX
Locations
-
Primary
Get directions
13208 E Shea Blvd. Suite 100
Scottsdale, Arizona 85259, US
-
Get directions
18322 Bothell Everett Hwy
Bothell, Washington 98012, US
Employees at TD2 Oncology
Updates
-
Erin Trachet will be presenting at Tumor Models San Francisco on January 28 at 2:15 PM! Her talk will explore emerging data linking obesity-driven inflammation to immunotherapy response, highlighting how metabolic modulation with GLP-1 receptor agonists may influence tumor growth, immune cell populations, and response to PD-1 blockade in preclinical models. Hope to see you there! #TumorModelsSF #ImmunoOncology #CancerMetabolism #TD2Oncology #OncologyCRO #PD1 #GLP1
-
-
As oncology development becomes increasingly complex, therapeutic depth and execution matter more than ever. Thank you to Donald Hooker, CFA and Bourne Partners for the thoughtful analysis!
We, at Bourne Partners, were excited by the news this week that Worldwide Clinical Trials announced plans to acquire Catalyst Clinical Research, representing what we believe to be one of the larger contract research organization (CRO) acquisitions in recent years -- as well as a possible sign that M&A activity in the CRO space may be returning. We believe that CRO valuations have generally recovered from a low point in 2025 as investors have gained more visibility to (and comfort with) the regulatory backdrop and as pharma companies have adjusted their product development strategies to the post-IRA legislative environment. For Worldwide Clinical Trials, the acquisition of Catalyst Clinical Research adds significant early phase oncology expertise and a strong functional service provider (FSP) business -- as well as incremental capabilities in artificial intelligence (AI), biometrics, and medical writing. In our recent Bourne Partners Deep-Dive CRO Report and our podcast with specialty oncology CRO TD2 Oncology we have highlighted that therapeutic subject matter expertise is increasingly competitively relevant for CROs given the rising industry focus on rare diseases and conditions. To be competitive, it is critical for a CRO to have a reputation (and track record) in key therapeutic verticals. In particular, oncology is anticipated to remain the top therapeutic area for pharma over the next five years, supported by the rise of new treatment modalities -- such as cell/gene therapies, anti-drug conjugates, and radiopharma. In fact, the IQVIA Institute expects as many as 100 novel cancer medicines to be developed and launched over the next five years. In our view, the complexity inherent to cancer research tends to result in more outsourcing to CROs. In fact, we hear that the use of CROs is much more common in oncology research with outsourcing rates as high as ~75%-85% (vs ~40%-50% in other areas). Bourne Partners is very active in the CRO space. For more, refer to our recently published 61-page Deep-Dive Report on the CRO space here: https://lnkd.in/eVKcAxHi -- as well as our recent podcast discussion with specialty oncology CRO TD2 here: https://lnkd.in/ekdbXNbS Also, you can directly reach out to me -- or to our pharma services banking team led by Jeremy Johnson (jjohnson@bourne-partners.com), James West (jwest@bourne-partners.com) Jake Curtis (jcurtis@bourne-partners.com), and Ryan Silvester (rsilvester@bourne-partners.com).
-
-
Radioligand therapies are moving fast, and first in human planning has never been more critical. Join us for a focused webinar on FIH clinical trial planning for radiopharmaceuticals, where we will break down what it really takes to move from IND strategy to patient dosing with confidence. If you are developing or planning an RLT program, this session is built for you. Register here: https://hubs.li/Q03-zbpf0
-
-
Combination therapies are reshaping how we approach resistant and aggressive cancers. This collaboration with Panome Bio demonstrates how deep metabolic insight can help explain why certain drug combinations succeed and how that knowledge can guide smarter preclinical development.
New Blog Post: A Metabolic Blueprint for Synergistic Cancer Therapy Cancer rarely responds to a single attack. As tumors adapt and develop resistance, especially in aggressive subtypes like KRAS/LKB1-mutant non-small-cell lung cancer, combination therapies are becoming essential. But understanding why certain combinations work remains a major challenge. In our latest blog, we highlight a collaboration between Panome Bio and TD2 Oncology, where Next-Generation Metabolomics® was used to uncover the metabolic mechanisms behind a synergistic drug combination in a preclinical KRAS/LKB1-mutant NSCLC model. 👉 Read the full blog: https://hubs.ly/Q03-pQL40
-
We are heading to San Francisco for JPM! Catch up with Stephen Gately, Tara Franks, Chris Clark, and Bill Donovan to discuss your oncology development programs and plans for 2026.
-
-
Receptor mediated therapies continue to redefine what precision looks like in modern oncology. As Alan Miller MD, PhD shared during our recent webinar, translating mechanism into meaningful clinical impact requires intentional trial design and early, mechanism driven insight. In our latest blog, we explore how receptor mediated therapies are evolving in the clinic and what sponsors should consider as these programs advance from targeting to patient impact. Read the full blog: https://hubs.li/Q03ZTn1R0
-
Happy New Year from our team at TD2 Oncology! As we welcome the new year, we want to take a moment to reflect on what 2025 brought us. While the broader market presented challenges, we continued to make meaningful progress through thoughtful collaboration, new and ongoing partnerships, and expanded work across key areas of oncology research, including radioligand therapies and antibody-drug conjugates. These efforts reflect our continued commitment to rigorous, science led decision making, ensuring each program is guided by evidence, insight, and thoughtful strategy at every stage. Looking ahead to 2026, we are encouraged by the direction of oncology innovation. As treatments become increasingly precise and personalized, we remain focused on science driven strategy and operational excellence to advance promising therapies at every stage of development. Thank you to our clients, collaborators, and colleagues for a successful year. We look forward to what we will accomplish together in 2026!
-
-
Merry Christmas & Happy Holidays from all of us at TD2 Oncology! Thank you to our clients, colleagues, and collaborators for a wonderful year. We’re grateful for the partnerships and progress, and we look forward to what’s ahead in 2026. #HappyHolidays #MerryChristmas #TD2Oncology #OncologyCRO
-
-
So grateful for our team and their generosity this holiday season! Together, we donated 89 gifts to the Children's Cancer Network’s toy drive to help brighten the holidays for children facing cancer. Moments like this remind us why community matters.
-